Clinical trials: Bortezomib
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma
This phase II trial studies the side effects and how well lower doses of bortezomib, dexamethasone, and cyclophosphamide work in treating older patients with multiple myeloma.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT02082405
- Testing
- bortezomib, cyclophosphamide, dexamethasone
- Sponsor
- Case Comprehensive Cancer Center
Plasma Cell Myeloma, Renal Failure
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
This phase II trial studies how well daratumumab-based therapy works in treating patients with newly diagnosed multiple myeloma with kidney failure.
- Trial name
- NCT04352205
- Testing
- Bortezomib, Daratumumab, Dexamethasone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Emory University
Multiple Myeloma
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or…
- Trial name
- NCT02206425
- Testing
- Melphalan, Prednisone, Cyclophosphamide
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma, Peripheral Neuropathy
Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients
In the present study we are planning to study electrophysiological changes related to the dose and time of bortezomib administration in newly diagnosed patients with MM, during the first months of treatment and 6 months after…
- Trial name
- NCT00872352
- Testing
- EMG
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Wolfson Medical Center
Multiple Myeloma
GEM05 for Patients With Multiple Myeloma More Than 65 Years Old
The primary objective is to analyze and compare the efficacy, the response rate, the CR and the response rate duration of both induction treatments and both maintenance treatments
- Trial name
- NCT00443235
- Testing
- Melphalan/Prednisone/Velcade, Thalidomide/Prednisone/Velcade
- Where
- 77 sites in Spain
- Volunteers
- 260 people
- Sponsor
- PETHEMA Foundation
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. This phase II trial is studying how well bortezomib works in treating patients with advanced transitional cell carcinoma of…
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer
- Trial name
- NCT00072150
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients
The purpose of this study is to determine whether doxorubicin HCL liposome injection, bortezomib, and Dexamethasone in combination, are effective in previously untreated multiple myeloma patients.
- Trial name
- NCT00561743
- Testing
- Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone
- Volunteers
- 50 people
- Sponsor
- Janssen-Ortho Inc., Canada
Mantle Cell Lymphoma
Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
The purpose of this study is to determine the safety and clinical efficacy of the combination of panobinostat plus bortezomib.
- Trial name
- BUS48T (NCT01504776)
- Testing
- Panobinostat, Bortezomib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Anand Jillella
Multiple Myeloma
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma
- Trial name
- NCT01720043
- Testing
- Velcade
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Utah
Multiple Myeloma
Bortezomib Consolidation Trial
The aim of this trial is to determine whether bortezomib improves response and delays progression for multiple myeloma patients after high dose therapy and autologous stem cell transplant.
- Trial name
- BCT (NCT01517724)
- Testing
- Bortezomib
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University College, London
Relapsed or Refractory Multiple Myeloma
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and…
- Trial name
- NCT07018050
- Testing
- QLS32015, Pomalidomide, Dexamethasone
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Various drugs have been added to different treatment regimens in order to improve the response rate in patients with Acute Lymphoblastic Leukemia, however, it has been shown that adding Bortezomib to the relapsing regimen…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease
- Trial name
- NCT05137860
- Testing
- Bortezomib
- Where
- Mexico
- Volunteers
- 56 people
- Sponsor
- Hospital General de Mexico
Multiple Myeloma
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
The purpose of this study is to better understand what effects Bortezomib, a drug used for multiple myeloma therapy, has on the immune system.
- Trial name
- NCT01472627
- Testing
- Blood draws
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
The main objective of this study is to assess the long-term effectiveness of SCIO-469 as monotherapy, or in combination with bortezomib in relapsed, refractory patients with multiple myeloma (MM) who have previously demonstrated…
- Trial name
- NCT00095680
- Testing
- SCIO-469, SCIO-469 and bortezomib
- Volunteers
- 30 people
- Sponsor
- Scios, Inc.
Multiple Myeloma, Refractory
Alvocade® (Bortezomib) Safety and Effectiveness Study
This study is a phase IV, post-marketing, observational, cohort study for safety and effectiveness evaluation of Alvocade® use in Iranian patients with multiple myeloma. No control groups were considered in the study design.
- Trial name
- NCT06012383
- Testing
- Bortezomib
- Volunteers
- 57 people
- Sponsor
- NanoAlvand
Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This randomized phase II trial is studying bortezomib and irinotecan to see how well they work compared to bortezomib alone in treating patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck.
- Conditions
- Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx
- Trial name
- NCT00103259
- Testing
- bortezomib, irinotecan hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
Explore stem cell collection with or without bortezomib with in-vivo purging in multiple myeloma.
- Trial name
- NCT02703779
- Testing
- Bortezomib, Granulocyte colony-stimulating factor (G-CSF), Mozobil
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Siddhartha Ganguly
Multiple Myeloma
Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma
The purpose of this study is to determine the tolerance and potential efficacy of combining dose intense melphalan with escalating doses of bortezomib in patients with multiple myeloma undergoing autologous stem cell…
- Trial name
- Mel-Vel (NCT00784823)
- Testing
- Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Hackensack Meridian Health
High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies how well rituximab, venetoclax, and bortezomib work in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory).
- Conditions
- High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Trial name
- NCT04285268
- Testing
- Bortezomib, Rituximab, Venetoclax
- Where
- United States
- Sponsor
- Rutgers, The State University of New Jersey
Myeloma
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
A real-world prospective registry study for patients with newly diagnosed multiple myeloma (NDMM) has been conducted at the First Affiliated Hospital of Soochow University since August 2018.
- Trial name
- NCT07206810
- Testing
- Bortezomib, Lenalidomide, and Dexamethasone
- Where
- China
- Volunteers
- 419 people
- Sponsor
- The First Affiliated Hospital of Soochow University